Osteoporosis after adjuvant treatment for early-stage breast cancer.
CONCLUSIONS: Adjuvant anthracycline-taxane-based chemotherapy followed by endocrine therapy caused bone loss, especially in younger compared with older patients with early-stage breast cancer, confirming the results from randomised trials.
FUNDING: This work was supported by the Region of Southern Denmark (grant number 13/7078); the University of Southern Denmark (grant number 00-101-000); the Danish Cancer Society (grant number R90-A6210-14-52); the Department of Oncology and Department of Endocrinology, Odense University Hospital; and the Consultant Council Scholarship, Odense University Hospital.
TRIAL REGISTRATION: The study was approved by the Ethics Committee in Region of Southern Denmark (Project ID S-20140142) and the Danish Data Protection Board (ID 2008-58-0035).
PMID: 33215600 [PubMed - in process]
Source: Danish Medical Journal - Category: General Medicine Tags: Dan Med J Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Denmark Health | DEXA Scan | Endocrine Therapy | Endocrinology | General Medicine | Grants | Medical Ethics | Orthopaedics | Osteoporosis | PET Scan | Study